"A surgeon in London says he has performed the UK's first long-distance robotic operation," reports the BBC, "on a patient located 1,500 miles (2,400km) away..." Leading robotic urological surgeon Professor Prokar Dasgupta said it felt "almost as if I was there" as he carried out a prostate removal on [62-year-old] Paul Buxton... It is hoped that remote robotic surgery could spare future patients the "vast expense and inconvenience" of travelling for treatment, and help deliver better healthcare to people in more remote locations... Buxton had expected to be put on an NHS waiting list after receiving a shock prostate cancer diagnosis just after Christmas, but he "jumped at the chance" to be the first patient to undergo the treatment remotely as part of a trial. "A lot of people actually said to me: 'You're not going to do it, are you?' "I thought, I'm giving something back here," he said... The operation was performed from The London Clinic using a robot equipped with a 3D HD camera and four arms, all controlled through a console with a delay of only 0.06 seconds. The console in the UK was connected to the robot in Gibraltar via fibre-optic cables, with a backup 5G link. A team in Gibraltar remained on standby in case the connection failed, but it held throughout the procedure... Dasgupta will perform the procedure again on 14 March, which will be live-streamed to 20,000 world-leading urological surgeons at the European Association of Urology congress. He added: "I think it is very, very exciting, the humanitarian benefit is going to be significant." The U.K.'s National Health Service "is prioritising local robotic-assisted surgery," the article points out, "aiming for 500,000 robot-supported operations a year by 2035." Thanks to Slashdot reader fjo3 for sharing the article.

Read more of this story at Slashdot.

Long-time Slashdot reader fjo3 shared this report from Agence France-Presse: Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients within months. Pharmaceutical company Sumitomo Pharma said it received the green light for the manufacture and sale of Amchepry, its Parkinson's disease treatment that transplants stem cells into a patient's brain. Japan's health ministry also gave the go-ahead to ReHeart, heart muscle sheets developed by medical startup Cuorips that can help form new blood vessels and restore heart function, media reports said. The treatments could be on the market and rolled out to patients as early as this summer, reports said, citing the health ministry, becoming the world's first commercially available medical products using induced pluripotent stem cells... In a statement, Sumitomo Pharma said it had obtained "conditional and time-limited approval" for the manufacture and marketing of Amchepry under a system which is reportedly designed to get these products to patients as quickly as possible. The approval is a kind of "provisional license", the Asahi newspaper said, after the safety and efficacy of the treatment was judged based on data from fewer patients than in ordinary clinical trials for drugs. A trial led by Kyoto University researchers indicated that the company's treatment was safe and successful in improving symptoms. The study involved seven Parkinson's patients aged between 50 and 69, with each receiving a total of either five million or 10 million cells implanted on both sides of the brain... The patients were monitored for two years and no major adverse effects were found, the study said. Four patients showed improvements in symptoms. The article notes that "Worldwide, about 10 million people have the illness, according to the Parkinson's Foundation," while also notes that today's current therapies "improve symptoms without slowing or halting the disease progression..."

Read more of this story at Slashdot.

alternative_right shares a report from ScienceAlert: According to a study of 38 adult human brains donated to science, superagers -- people who retain exceptional memory as they age -- have roughly twice as many immature neurons as their peers who age more typically. Moreover, people with Alzheimer's disease show a marked reduction in neurogenesis compared to a normal baseline. [...] Led by researchers at the University of Illinois Chicago, the team set out to examine a variety of postmortem hippocampal tissue samples to see if they could identify markers of neurogenesis -- and if different groups had any notable differences. The brain samples were donated from five groups: eight healthy young adults, aged between 20 and 40; eight healthy agers, aged between 60 and 93; six superagers, aged between 86 and 100; six individuals with preclinical Alzheimer's pathology, aged between 80 and 94; and 10 individuals with an Alzheimer's diagnosis, aged between 70 and 93. The young healthy adult brain tissue was first analyzed to establish the neurogenesis pathways in the adult brain. Then, they analyzed 355,997 individual cell nuclei isolated from the hippocampus, searching for three different stages of cell development: Stem cells, which can develop into neurons; neuroblasts, which are stem cells in the process of that development; and immature neurons, on the verge of functionality. The results were striking. "Superagers had twice the neurogenesis of the other healthy older adults," [says neuroscientist Orly Lazarov of the University of Illinois Chicago]. "Something in their brains enables them to maintain a superior memory. I believe hippocampal neurogenesis is the secret ingredient, and the data support that." That's an interesting result on its own, but the data from the individuals with preclinical Alzheimer's pathology and Alzheimer's diagnoses is where the real meat of the study sits. In the preclinical group, subtle molecular changes hinted that the system supporting new neuron growth was beginning to falter. In the Alzheimer's group, a clear drop in immature neurons was evident. A genetic analysis of the nuclei also showed that superager neural cells have increased gene activity linked to stronger synaptic connections, greater plasticity, and brain-derived neurotrophic factor, a critical protein for neural survival, growth, and maintenance. Taken together, these three things can be interpreted as resilience. The research has been published in the journal Nature.

Read more of this story at Slashdot.